Related Experiment Videos
Tetanus immunity in patients with hematological malignancies
V Hamarström1, K Pauksen, H Svensson
1Department of Hematology, Karolinska Institute, Huddinge University Hospital, Sweden.
Summary
Patients with hematological diseases often lose immunity to tetanus toxoid after chemotherapy. Advanced age, lymphoid malignancy, and disease stage increase the risk of tetanus non-immunity in these patients.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Chemotherapy for hematological malignancies can impact long-term immune function.
- Tetanus toxoid vaccination is crucial for maintaining immunity against tetanus.
- Assessing tetanus immunity in immunocompromised patients is vital for public health.
Purpose of the Study:
- To evaluate long-term immunity to tetanus toxoid in patients with hematological diseases post-chemotherapy.
- To identify risk factors associated with loss of tetanus immunity in this patient cohort.
Main Methods:
- Study included 206 patients with various hematological malignancies.
- Seronegativity rates for tetanus were assessed across different patient groups.
- Multivariate logistic regression analysis was employed to identify independent risk factors.
Main Results:
- Significant variation in tetanus seronegativity rates (20-70%) was observed among patient groups.
- Non-immunity rates were notably high in Acute Myeloid Leukemia (AML) (36%), Acute Lymphoblastic Leukemia (ALL) (56%), lymphoma (54%), and myeloma (31%).
- Increasing age, lymphoid malignancy, and advanced disease stage were identified as independent risk factors for tetanus non-immunity.
Conclusions:
- Patients with hematological malignancies treated with chemotherapy exhibit a high prevalence of tetanus non-immunity.
- Age, disease type (lymphoid), and stage are critical determinants of long-term tetanus immunity loss.
- Routine monitoring and potential booster vaccinations for tetanus should be considered in these vulnerable patients.